Description
Springer Controversies in the Management of Gynecological Cancers 1st Editon 2016 Softbound by Jonathan A. Ledermann, Carien L. Creutzberg, Michael A. Quinn
This is a novel text that highlights the controversial areas in the management of gynecological cancers. None of the topics in this book have definitive answers; they represent the everyday decision-making facing gynecologists, oncologists, radiologists, pathologists and other health professionals treating women with these conditions. This book is not to be used as a traditional textbook; it is a text that specialists and trainees will use to help them weigh up the arguments that exist in a variety of areas in the treatment of gynecological cancers. Each chapter will have two or more authors, selected either for their opposing views or for their ability to provide an opposite view or opinion to the other. The content will be evidence-based, illustrating contrasting evidence and scientific opinion in the literature. Each chapter will close on a summary indicating the direction of research needed to address the issues being discussed. 1. Controversies in the Treatment of Women with Early Stage Epithelial Ovarian Cancer.- 2. Recurrent Ovarian Cancer: When to Treat and How to Assess.- 3. New Views of Ovarian Carcinoma Types: How will this Change Practice?.- 4. Lymphadenectomy in Endometrial Cancer: The Controversy Rages Unabated.- 5. What is the Role of Adjuvant Radiotherapy and Chemotherapy in Endometrial Cancer?.- 6. Chemotherapy and/or Targeted Therapies for Advanced Endometrial Cancer: Time to Rethink?.- 7. Is Cervix Cancer a Disappearing Disease? Impact of HPV Vaccination in Developed Countries.- 8. What is the Role of Cytotoxic Chemotherapy in Advanced Cervical Cancer?.- 9. Response as a Measure of Treatment Efficacy in Clinical Trials: Should RECIST Be Abandoned?.- 10. What are the Treatment Options for Recurrent Ovarian Cancer?.- 11. How To Study Rare Gynaecological Tumours: Trials or Registries?.- 12. What is the Best Treatment Model for Gynaecological Cancers? Does Centralization Help?.- 13. When Should Surgery be Performed for the First-Line Treatment of Advanced Ovarian Cancer?.- 14. Does Intraperitoneal Therapy for Ovarian Cancer have a Future?.- 15. Maintenance Therapy for First-Line Treatment of Ovarian Cancer—Is this the Strategy for the Future?.- 16. What is the Value of Lymphadenectomy in Early Ovarian Cancer?.- 17. Sentinel Node Biopsy—Does it Help in the Management of Vulvar Cancer?.- 18. Controversies in the Management of Advanced Vulvar Cancer.- 19. Bowel Obstruction in Ovarian Cancer: To Operate or Not?.- 20. Early Cervical Cancer: Can Fertility be Safely Preserved?.- 21. What is the Role of PET/CT in Gynaecologic Cancers?.- 22. Do Intensity-Modulated Radiation, Image-Guided Radiation, and 3D Brachytherapy Significantly Advance Radiotherapeutic Management of Gynecologic Cancers?.- 23. What is the Place of Hormone Replacement Therapy in Ovarian, Endometrial, and Breast Cancer?.- 24. Familial Gynaecological Cancers: Whom to Screen and How to Manage?.- 25. Trial Design: Should Randomized Phase III Trials in Gynaecological Cancers be Abandoned?.- 26. How Should Early Gestational Trophoblastic Disease be Managed?.- 27. Should Every Woman with Gynaecologic Cancer Undergo Routine Screening for Psychological Distress and Sexual Dysfunction?.- 28. How Should Gynaecological Sarcomas be Managed?.- 29. What is the Future of Immunotherapy in Ovarian Cancer?.